150 related articles for article (PubMed ID: 32808785)
1. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
Surve DH; Jirwankar YB; Dighe VD; Jindal AB
Mol Pharm; 2020 Oct; 17(10):3990-4003. PubMed ID: 32808785
[TBL] [Abstract][Full Text] [Related]
2. Layer-by-Layer Assembled Nanostructured Lipid Carriers for CD-44 Receptor-Based Targeting in HIV-Infected Macrophages for Efficient HIV-1 Inhibition.
Mahajan K; Rojekar S; Desai D; Kulkarni S; Bapat G; Zinjarde S; Vavia P
AAPS PharmSciTech; 2021 Jun; 22(5):171. PubMed ID: 34100170
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
Leporati A; Gupta S; Bolotin E; Castillo G; Alfaro J; Gottikh MB; Bogdanov AA
Pharm Res; 2019 Mar; 36(5):73. PubMed ID: 30919089
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of reverse-phase high-performance liquid chromatographic (RP-HPLC) method for quantification of Efavirenz in Efavirenz-Enfuvirtide co-loaded polymer-lipid hybrid nanoparticles.
Surve DH; Jindal AB
J Pharm Biomed Anal; 2019 Oct; 175():112765. PubMed ID: 31349211
[TBL] [Abstract][Full Text] [Related]
5. Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: physicochemical, molecular, microstructural, and stability evaluation.
Pokharkar VB; Jolly MR; Kumbhar DD
Eur J Pharm Sci; 2015 Apr; 71():99-111. PubMed ID: 25708940
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration.
Thanki K; van Eetvelde D; Geyer A; Fraire J; Hendrix R; Van Eygen H; Putteman E; Sami H; de Souza Carvalho-Wodarz C; Franzyk H; Nielsen HM; Braeckmans K; Lehr CM; Ogris M; Foged C
J Control Release; 2019 Sep; 310():82-93. PubMed ID: 31398360
[TBL] [Abstract][Full Text] [Related]
9. Preformulation studies of efavirenz with lipid excipients using thermal and spectroscopic techniques.
Makoni PA; Kasongo KW; Walker RB
Pharmazie; 2020 Sep; 75(9):417-423. PubMed ID: 32797766
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study.
Varshosaz J; Taymouri S; Jahanian-Najafabadi A; Alizadeh A
IET Nanobiotechnol; 2018 Sep; 12(6):795-806. PubMed ID: 30104454
[TBL] [Abstract][Full Text] [Related]
11. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation.
Pardeshi CV; Belgamwar VS; Tekade AR; Surana SJ
J Mater Sci Mater Med; 2013 Sep; 24(9):2101-15. PubMed ID: 23728521
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
13. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
[TBL] [Abstract][Full Text] [Related]
14. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
15. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
16. Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide.
Ariza-Sáenz M; Espina M; Calpena A; Gómara MJ; Pérez-Pomeda I; Haro I; García ML
Mol Pharm; 2018 Nov; 15(11):5005-5018. PubMed ID: 30226777
[TBL] [Abstract][Full Text] [Related]
17. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
Kumar P; Lakshmi YS; Kondapi AK
HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
[TBL] [Abstract][Full Text] [Related]
18. Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion Solvent Evaporation: In vitro and In vivo Evaluation.
Dalvi BR; Siddiqui EA; Syed AS; Velhal SM; Ahmad A; Bandivdekar AB; Devarajan PV
Curr Drug Deliv; 2016; 13(7):1071-1083. PubMed ID: 26777885
[TBL] [Abstract][Full Text] [Related]
19. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
